Close Menu

NEW YORK – The UK's National Institute for Healthcare Excellence (NICE) on Thursday recommended the National Health Service make acalabrutinib (AstraZeneca's Calquence) available as a treatment for previously untreated chronic lymphocytic leukemia with a 17p deletion or TP53 mutation.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.